Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL

Jennifer A. Woyach; Amy S. Ruppert; Nyla A. Heerema; Weiqiang Zhao; Allison M. Booth; Wei Ding; Nancy L. Bartlett; Danielle M. Brander; Paul M. Barr; Kerry A. Rogers; Sameer A. Parikh; Steven Coutre; Arti Hurria; Jennifer R. Brown; Gerard Lozanski; James S. Blachly; Hatice G. Ozer; Brittny Major-Elechi; Briant Fruth; Sreenivasa Nattam; Richard A. Larson; Harry Erba; Mark Litzow; Carolyn Owen; Charles Kuzma; Jeremy S. Abramson; Richard F. Little; Scott E. Smith; Richard M. Stone; Sumithra J. Mandrekar; John C. Byrd

Journal ArticleOPEN ACCESS

Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL

Woyach J
Ruppert A
Heerema N
et al.

New England Journal of Medicine (2018) 379(26) 2517-2528

DOI: 10.1056/nejmoa1812836

829Citations

550Readers

Abstract

Abstract Background Ibrutinib has been approved by the Food and Drug Administration for the treatment of patients with untreated chronic lymphocytic leukemia (CLL) since 2016 but has not been compa...

Cite

CITATION STYLE

APA

Woyach, J. A., Ruppert, A. S., Heerema, N. A., Zhao, W., Booth, A. M., Ding, W., … Byrd, J. C. (2018). Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. New England Journal of Medicine, 379(26), 2517–2528. https://doi.org/10.1056/nejmoa1812836

Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL

Abstract

Cite

Register to see more suggestions